A-85380 [3-(2(S)-azetidinylmethoxy)pyridine]: In vitro pharmacological properties of a novel, high affinity alpha 4 beta 2 nicotinic acetylcholine receptor ligand

被引:120
作者
Sullivan, JP
DonnellyRoberts, D
Briggs, CA
Anderson, DJ
Gopalakrishnan, M
PiattoniKaplan, M
Campbell, JE
McKenna, DG
Molinari, E
Hettinger, AM
Garvey, DS
Wasicak, JT
Holladay, MW
Williams, M
Arneric, SP
机构
[1] Neuroscience Discovery, Pharmaceutical Products Division, Abbott Laboratories, Abbott Park
[2] Neuroscience D47W, Pharmaceutical Products Division, Abbott Laboratories, Abbott Park
关键词
ACh acetylcholine; alpha-BgT alpha-bungarotoxin; DH beta E dihydro-beta-erythroidine; MLA methyllycaconitine; nAChR nicotinic acetylcholine receptor;
D O I
10.1016/0028-3908(96)84644-2
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The in vitro pharmacological properties of a novel cholinergic channel ligand, A-85380 [3-(2(S)-azetidinylmethoxy)pyridine], were examined using tissue preparations that express different putative nAChR subtypes. In radioligand binding studies, A-85380 is shown to be a potent and selective ligand for the human alpha 4 beta 2 nAChR subtype (K-i = 0.05 +/- 0.01 nM) relative to the human alpha 7 (K-i = 148 +/- 13 nM) and the muscle alpha 1 beta 1dg subtype expressed in Torpedo electroplax (K-i = 314 +/- 12 nM). The R-enantiomer of A-85380, A-159470, displays little enantioselectivity towards the alpha 4 beta 2 and alpha 1 beta 1 delta gamma subtypes but does display 12-fold enantioselectivity towards the alpha 7 subtype (K-i = 1275 +/- 199 nM). (+)- and (-)-Epibatidine display similar potencies at the human human alpha 4 beta 2 (K-i = 0.04 +/- 0.02 nM and 0.07 +/- 0.02 nM, respectively), human alpha 7 (K-i = 16 +/- 2 nM and 22 +/- 3 nM, respectively) and muscle alpha 1 beta 1 delta g (K-i = 2.5 +/- 0.9 nM and 5.7 +/- 1.0 nM, respectively) nAChRs. Functionally, A-85380 is a potent activator of cation efflux through the human alpha 4 beta 2 (EC(50) = 0.7 +/- 0.1 mu M) and ganglionic (EC(50) = 0.8 +/- 0.04 mu M) subtypes,effects that are attenuated by pretreatment with mecamylamine (10 mu M). Further, A-85380 can activate (EC(50) = 8.9 +/- 1.9 mu M) currents through channels formed by injection of the human alpha 7 subunit into Xenopus oocytes, effects that are attenuated by pretreatment with the alpha 7 nAChR antagonist, methyllycaconitine (10 nM). In all cases, A-85380 is more potent than (-)-nicotine but less potent than (+/-)-epibatidine. In neurotransmitter release studies, A-85380 stimulates the release of dopamine with an EC(50) value of 0.003 +/- 0.001 mu M which is equipotent to (+/-)-epibatidine, and 20-fold more potent that (-)-nicotine (EC(50) = 0.04 +/- 0.009 mu M). Thus, A-85380 displays a profile of robust activation of a number of nAChR subtypes with substantially less affinity for [I-125]alpha-BgT sites than [H-3](-)-cytisine sites, suggesting that it may serve as a more selective pharmacologic probe for the alpha 4 beta 2 subtype relative to the alpha 7 and alpha 1 beta 1 delta g nAChRs than (+/-)-epibatidine. Copyright (C) 1996 Elsevier Science Ltd.
引用
收藏
页码:725 / 734
页数:10
相关论文
共 41 条
  • [1] Novel 3-pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors
    Abreo, MA
    Lin, NH
    Garvey, DS
    Gunn, DE
    Hettinger, AM
    Wasicak, JT
    Pavlik, PA
    Martin, YC
    DonnellyRoberts, DL
    Anderson, DJ
    Sullivan, JP
    Williams, M
    Americ, SP
    Holladay, MW
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (04) : 817 - 825
  • [2] ANAND R, 1993, MOL PHARMACOL, V44, P1046
  • [3] ARNERIC SP, 1994, J PHARMACOL EXP THER, V270, P310
  • [4] Arneric Stephen P., 1995, P95
  • [5] BADIO B, 1994, MOL PHARMACOL, V45, P563
  • [6] PHARMACOLOGICAL PROPERTIES OF THE HOMOMERIC ALPHA-7 RECEPTOR
    BERTRAND, D
    BERTRAND, S
    BALLIVET, M
    [J]. NEUROSCIENCE LETTERS, 1992, 146 (01) : 87 - 90
  • [7] GANGLIONIC NICOTINIC ACETYLCHOLINE-RECEPTOR ACTIVATION BY THE NOVEL AGONIST ABT-418
    BRIGGS, CA
    HUGHES, ML
    MONTEGGIA, LM
    GIORDANO, T
    DONNELLYROBERTS, D
    ARNERIC, SP
    [J]. DRUG DEVELOPMENT RESEARCH, 1995, 34 (01) : 39 - 46
  • [8] HUMAN ALPHA-7 NICOTINIC ACETYLCHOLINE-RECEPTOR RESPONSES TO NOVEL LIGANDS
    BRIGGS, CA
    MCKENNA, DG
    PIATTONIKAPLAN, M
    [J]. NEUROPHARMACOLOGY, 1995, 34 (06) : 583 - 590
  • [9] THE FUNCTIONAL ARCHITECTURE OF THE ACETYLCHOLINE NICOTINIC RECEPTOR EXPLORED BY AFFINITY LABELING AND SITE-DIRECTED MUTAGENESIS
    CHANGEUX, JP
    GALZI, JL
    DEVILLERSTHIERY, A
    BERTRAND, D
    [J]. QUARTERLY REVIEWS OF BIOPHYSICS, 1992, 25 (04) : 395 - 432
  • [10] CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099